Description:
Reference Number: 1720
Background
There are a number of impediments to effective drug delivery. These can
include erroneous absorption which reduces the concentration of the drug at the
critical target site. In order to overcome this, researchers at the University
of Strathclyde have pioneered a technique which delivers drugs through the use
of a proprietary delivery system.
Technology
Our proprietary delivery systems are microscopic shipping vessels which act
as transporters of the entrapped drug and preferentially target it to phagocytic
cells within a tissue. Administration of these drug loaded particles by
inhalation allows non-invasive drug delivery to be realised, minimising repeat
administrations due to increased efficacy. This platform technology can be used
for a number of applications in treatment of lung conditions such as infectious
diseases, cancer, asthma, or emerging diseases such as SARS.
Key Benefits
- Reductions in drug doses given and concentrations can be achieved due to
the increased efficiency of the system
- Toxic drugs can be given in lower quantities
- Different types of formulations can be produced
Markets and Applications
The market potential of this delivery system is broad as it is a platform
technology. Previous studies have already demonstrated that the delivery system
can deliver drugs after intravenous injection and new studies focus on the use
of this technology for lung delivery.
Licensing and Development
Our proprietary delivery system has been patented and is owned by the
University of Strathclyde. Contact is welcomed from organisations interested in
developing, licensing or exploiting this technology.
For further information, please contact Research & Knowledge Exchange
Services:
e: rkes@strath.ac.uk t: 0141 548 3707 f: 0141 552 4409
This project has received assistance from the Proof of Concept Programme
managed by Scottish Enterprise. The Proof of Concept Programme supports the
pre-commercialisation of leading-edge technologies emerging from Scotland's
universities, research institutes and NHS Trusts.